Found: 24
Select item for more details and to access through your institution.
Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment.
- Published in:
- Cancers, 2021, v. 13, n. 24, p. 6239, doi. 10.3390/cancers13246239
- By:
- Publication type:
- Article
Photodynamic Priming Improves the Anti-Migratory Activity of Prostaglandin E Receptor 4 Antagonist in Cancer Cells In Vitro.
- Published in:
- Cancers, 2021, v. 13, n. 21, p. 5259, doi. 10.3390/cancers13215259
- By:
- Publication type:
- Article
Malignant Ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and Therapy Response.
- Published in:
- Cancers, 2021, v. 13, n. 17, p. 4318, doi. 10.3390/cancers13174318
- By:
- Publication type:
- Article
EP4 and Class III β-Tubulin Expression in Uterine Smooth Muscle Tumors: Implications for Prognosis and Treatment.
- Published in:
- Cancers, 2019, v. 11, n. 10, p. 1590, doi. 10.3390/cancers11101590
- By:
- Publication type:
- Article
Early Implementation of Robotic Training in Surgical and Surgical Subspecialty Residency.
- Published in:
- American Surgeon, 2024, v. 90, n. 6, p. 1317, doi. 10.1177/00031348241229631
- By:
- Publication type:
- Article
Review of Immune Therapies Targeting Ovarian Cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo.
- Published in:
- Cancer (0008543X), 2015, v. 121, n. 3, p. 403, doi. 10.1002/cncr.29062
- By:
- Publication type:
- Article
Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.
- Published in:
- Cancer (0008543X), 2013, v. 119, n. 14, p. 2582, doi. 10.1002/cncr.28017
- By:
- Publication type:
- Article
Pap smear outcomes in elderly women living with HIV and HIV-negative matched controls.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis.
- Published in:
- Journal of Translational Medicine, 2013, v. 11, n. 1, p. 1, doi. 10.1186/1479-5876-11-162
- By:
- Publication type:
- Article
Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Co-Packaged PARP inhibitor and photosensitizer for targeted photo-chemotherapy of 3D ovarian cancer spheroids.
- Published in:
- Cell & Bioscience, 2024, v. 14, n. 1, p. 1, doi. 10.1186/s13578-024-01197-6
- By:
- Publication type:
- Article
A novel small molecule LLL12B inhibits STAT3 signaling and sensitizes ovarian cancer cell to paclitaxel and cisplatin.
- Published in:
- PLoS ONE, 2021, v. 16, n. 4, p. 1, doi. 10.1371/journal.pone.0240145
- By:
- Publication type:
- Article
Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
- Published in:
- British Journal of Cancer, 2022, v. 126, n. 12, p. 1695, doi. 10.1038/s41416-022-01717-6
- By:
- Publication type:
- Article
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma.
- Published in:
- BMC Clinical Pathology, 2012, v. 12, n. 1, p. 22, doi. 10.1186/1472-6890-12-22
- By:
- Publication type:
- Article
A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability.
- Published in:
- Cancer (0008543X), 2022, v. 128, n. 6, p. 1206, doi. 10.1002/cncr.34025
- By:
- Publication type:
- Article
In vitro fertilization: a cross-sectional analysis of 58 US insurance companies.
- Published in:
- Journal of Assisted Reproduction & Genetics, 2023, v. 40, n. 3, p. 581, doi. 10.1007/s10815-022-02697-5
- By:
- Publication type:
- Article
Combined inhibition of IL-6 and IL-8 pathways suppresses ovarian cancer cell viability and migration and tumor growth.
- Published in:
- International Journal of Oncology, 2022, v. 60, n. 5, p. N.PAG, doi. 10.3892/ijo.2022.5340
- By:
- Publication type:
- Article
Risk, risk reduction and management of occult malignancy diagnosed after uterine morcellation: a commentary.
- Published in:
- Women's Health (17455057), 2015, v. 11, n. 6, p. 929, doi. 10.2217/whe.15.63
- By:
- Publication type:
- Article
Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.
- Published in:
- Women's Health (17455057), 2014, v. 10, n. 1, p. 45, doi. 10.2217/whe.13.72
- By:
- Publication type:
- Article
HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges.
- Published in:
- Archives of Pathology & Laboratory Medicine, 2014, v. 138, n. 3, p. 343, doi. 10.5858/arpa.2012-0416-RA
- By:
- Publication type:
- Article